Troy joins Sidley Austin Brown & Wood
This article was originally published in The Gray Sheet
Executive Summary
Former FDA Chief Counsel Dan Troy accepts position in firm's Life Sciences Practice & Appellate Litigation Group. He will focus on administrative and constitutional law and litigation, especially for the pharmaceutical, medical device and biotechnology industries, according to a Jan. 6 release. Colleen Klasmeier, who served as special assistant to the chief counsel under Troy, also is joining Sidley's Life Sciences Practice. Gerald Masoudi, formerly with Kirkland & Ellis, replaced Troy at FDA in November (1"The Gray Sheet" Nov. 22, 2004, p. 4)...
You may also be interested in...
Troy Advances Case For Preemption; Verdict On Liability Reform Still Pending
Product liability reform measures likely will have to include an alternative compensation program for injured consumers, former FDA Chief Counsel Daniel Troy said Jan. 26
FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.